Zacks Research Has Bullish Estimate for PBH Q1 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Equities researchers at Zacks Research boosted their Q1 2027 earnings per share estimates for Prestige Consumer Healthcare in a research report issued on Wednesday, May 28th. Zacks Research analyst R. Department now forecasts that the company will earn $1.26 per share for the quarter, up from their prior estimate of $1.11. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q3 2027 earnings at $1.26 EPS and FY2028 earnings at $5.18 EPS.

Several other research firms have also commented on PBH. Wall Street Zen upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. Oppenheimer upped their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Royal Bank of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. DA Davidson increased their target price on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Finally, Canaccord Genuity Group increased their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $93.33.

Prestige Consumer Healthcare Stock Performance

PBH stock traded up $1.30 during midday trading on Friday, reaching $85.78. 330,734 shares of the company's stock traded hands, compared to its average volume of 298,535. Prestige Consumer Healthcare has a 52-week low of $63.02 and a 52-week high of $90.04. The stock has a market cap of $4.24 billion, a P/E ratio of 20.09, a PEG ratio of 2.69 and a beta of 0.44. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The stock's 50-day moving average is $83.59 and its 200 day moving average is $82.42.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The firm had revenue of $296.52 million during the quarter, compared to analyst estimates of $289.36 million. During the same quarter in the prior year, the firm earned $1.02 EPS. The business's revenue for the quarter was up 7.0% compared to the same quarter last year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors have recently bought and sold shares of PBH. Kestra Investment Management LLC purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at about $27,000. CIBC Private Wealth Group LLC grew its stake in shares of Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after buying an additional 152 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of Prestige Consumer Healthcare in the 1st quarter worth approximately $38,000. Headlands Technologies LLC purchased a new position in Prestige Consumer Healthcare during the fourth quarter worth $40,000. Finally, Geneos Wealth Management Inc. boosted its stake in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after purchasing an additional 269 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP Mary Beth Fritz sold 1,678 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. This trade represents a 8.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.60% of the stock is currently owned by company insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.